Business
Exicure, Inc. Announces Termination of AbbVie and Ipsen Collaboration Agreements
- Exicure and AbbVie have terminated their agreement relating to the development programs targeting hair loss disorders - Exicure and Ipsen have terminated
About this update from Exicure, Inc.
[{"type":"text","content":"\n- Exicure and AbbVie have terminated their agreement relating to the development programs targeting hair loss disorders\n\n- Exicure and Ipsen have terminated their agreement relating to the development programs targeting Angelman syndrome and Huntington’s disease\n\n CHICAGO--(BUSINESS WIRE)--\nExicure, Inc. (NASDAQ: XCUR) an early-stage biotechnology company historically focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets, today announced the termination of its collaboration agreements with AbbVie, Inc. (AbbVie) and Ipsen BioPharm Limited (Ipsen).\n\nThrough separate agreements with AbbVie and Ipsen, Exicure was collaboratively advancing specified discovery programs in hair loss disorders and rare neurodegenerative disorders, respectively.\n\nAs a result of this termination, Exicure regains the ability to independently develop medicines targeting hair loss disorders, Angelman syndrome, and Huntington’s disease – whilst Ipsen retains the right to re-enter into the collaboration with Exicure in Huntington’s Disease and Angelman’s Syndrome\n\n“I want to thank both AbbVie and Ipsen for their support and partnership in these joint decisions. They were both tremendous companies to be associated with and extremely helpful and collaborative in developing and advancing the terminated discovery programs. In addition to these actions, Exicure is exploring strategic alternatives focused on maximizing stockholder value,” stated Matthias Schroff, Chief Executive Officer, Exicure.\n\nAbout Exicure\n\nExicure, Inc. is an early-stage biotechnology company historically focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The Company continues to actively pursue out-licensing opportunities for its clinical asset, cavrotolimod, as well as for its preclinical candidates, including the SCN9A program for neuropathic pain, and to pursue all strategic alternatives with the goal of maximizing stockholder value. For further information, see www.exicuretx.com.\n\nForward-Looking Statements\n\nThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements in this press release other than statements of historical fact may be deemed forward looking including, without limitation, stat...